NYSE · ABBV
Healthcare · Drug Manufacturers - General
$285.42
Up+$2.02 (+0.71%)
Updated Oct 19, 2026, 7:33 AM
SID Score
7.4/10
Composite research score
Smart Money
59/100
Neutral
Price performance · ABBV
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 16, 2026
ABBV closed at $285.42 after 20 trading sessions, up 7.92% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | $283.61 | $286.64 | $282.955 | $285.42 | 5.78M |
| Oct 15, 2026 | $288.28 | $291.40 | $282.81 | $283.40 | 7.62M |
| Oct 14, 2026 | $277.00 | $285.3999 | $275.97 | $283.48 | 5.63M |
| Oct 13, 2026 | $283.29 | $283.43 | $273.70 | $274.36 | 6.41M |
| Oct 12, 2026 | $277.65 | $281.30 | $276.01 | $281.12 | 5.59M |
| Oct 9, 2026 | $271.53 | $277.60 | $270.38 | $276.47 | 4.3M |
| Oct 8, 2026 | $270.98 | $272.515 | $265.71 | $272.42 | 5.49M |
| Oct 7, 2026 | $268.40 | $274.94 | $266.89 | $271.36 | 6.08M |
| Oct 6, 2026 | $267.74 | $268.8582 | $260.6197 | $266.69 | 4.5M |
| Oct 5, 2026 | $261.27 | $267.34 | $260.29 | $265.76 | 7.54M |
| Oct 2, 2026 | $259.74 | $264.06 | $257.87 | $262.82 | 5.86M |
| Oct 1, 2026 | $260.51 | $262.3158 | $259.00 | $259.93 | 3.89M |
| Sep 30, 2026 | $264.60 | $265.36 | $261.59 | $261.59 | 4.39M |
| Sep 29, 2026 | $265.45 | $268.93 | $261.5213 | $263.29 | 4M |
| Sep 28, 2026 | $264.33 | $267.735 | $263.38 | $266.28 | 4.43M |
| Sep 25, 2026 | $265.49 | $266.00 | $262.59 | $264.34 | 2.54M |
| Sep 24, 2026 | $265.37 | $267.41 | $263.09 | $265.12 | 3.46M |
| Sep 23, 2026 | $266.00 | $269.39 | $263.5885 | $265.08 | 3.47M |
| Sep 22, 2026 | $263.10 | $266.82 | $262.145 | $265.21 | 2.77M |
| Sep 21, 2026 | $263.07 | $266.5998 | $261.23 | $264.48 | 3.44M |
The latest Smart Investors Daily articles mentioning ABBV.
Company
Market Activity
Research & News
ABBV research
Company profile and research snapshot.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 13, 2026 | RBC Capital | Outperform | — |
| Oct 9, 2026 | UBS | Neutral | — |
| Oct 9, 2026 | Guggenheim | Buy | — |
| Oct 8, 2026 | Cantor Fitzgerald | Overweight | — |
| Oct 8, 2026 | JP Morgan | Overweight | — |
Generated Oct 18, 2026, 9:00 PM
AbbVie shares gained 0.71% today as investors digested positive Phase 3 lymphoma trial results showing a 51% DLBCL risk reduction, alongside continued recognition of the company's fortress dividend yield. The combination of clinical wins in oncology and stable dividend income is attracting both growth and income-focused investors.
Bottom line: AbbVie's modest gains reflect justified optimism around Phase 3 lymphoma data that could significantly expand its oncology footprint, combined with enduring appeal as a dividend aristocrat. While valuation at 16.4x appears fairly priced rather than discounted, the combination of clinical wins, stable cash generation, and insider buying supports a constructive medium-term outlook for patient capital.
Yahoo · Oct 18, 2026
AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.
Yahoo · Oct 18, 2026
AbbVie (NYSE: ABBV) today announced that new and updated data from its broad solid tumor portfolio will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking place October 23-27 in Madrid, Spain. Spanning multiple tumor types, therapeutic modalities and stages of development, the presentations represent AbbVie's most expansive ESMO program to date.
Yahoo · Oct 17, 2026
Rising rates can expose dividend traps, but this Dividend King is built to keep paying.
Yahoo · Oct 17, 2026
AbbVie (NYSE: ABBV) today announced the presentation of 20 new scientific abstracts from its IBD portfolio at the 2026 United European Gastroenterology (UEG) Week, October 17-20 in Barcelona, Spain. Together, the data reflect the breadth of AbbVie's research across IBD, including established therapies studied over longer treatment periods and in real-world clinical practice.
Interpretive context generated from the platform’s current data sources.
AbbVie Inc. shares traded at $285.42, reflecting a single-session decline of 1.32% per SID market data. Despite the daily pullback, the stock has demonstrated strong momentum across multiple timeframes, gaining 8.11% over the past month, 12.65% over the trailing three months, and 23.64% year-over-year. The stock currently trades well above both its 50-day moving average of $262.45 and its 200-day moving average of $234.75, indicating sustained bullish technical positioning according to Massive/Polygon data. The 14-day relative strength index stands at 71.0, placing ABBV just above the conventional overbought threshold of 70. AbbVie carries a beta of 0.334, reflecting substantially lower volatility relative to the broader market. Average daily trading volume registers at approximately 6.4 million shares, supporting consistent liquidity. The company's market capitalization stands at approximately $410.1 billion, positioning it among the largest firms in the healthcare sector.
AbbVie Inc. currently trades at a price-to-earnings ratio of 97.75, a significantly elevated multiple relative to historical healthcare sector averages, according to SID market data. The elevated P/E reflects earnings pressure tied to the company's ongoing transition away from Humira exclusivity and associated amortization costs. The PEG ratio stands at 1.25, suggesting the valuation remains more reasonable when adjusted for projected earnings growth, per SEC filings. AbbVie's price-to-book ratio registers at negative 126.33, a function of the company's negative book value driven by substantial goodwill impairments and debt accumulated through strategic acquisitions, including the Allergan transaction. The stock currently offers a dividend yield of approximately 2.87%, providing meaningful income for shareholders within the healthcare space. The combination of a high trailing P/E with a moderate PEG ratio indicates that the market is pricing in expectations of significant forward earnings recovery as newer growth franchises scale.
AbbVie Inc. carries a composite smart money score of 59 out of 100, reflecting a neutral overall signal per SID market data. Institutional ownership conviction scores an exceptionally high 25 out of 25, indicating robust accumulation among major fund managers as reported in 13F institutional filings. Insider activity scores 21 out of 25, bolstered by two insider purchases and zero insider sells recorded over the past 90 days according to SEC Form 4 filings. This exclusively buy-side insider activity suggests management confidence in the company's forward trajectory. Dark pool activity registers at a comparatively modest 9.8 out of 25, indicating limited off-exchange institutional block trading in recent periods. Congressional trading activity scores 3.2 out of 25, reflecting minimal disclosed legislative trading interest in the stock. The divergence between strong institutional and insider scores versus subdued dark pool and congressional metrics contributes to the overall neutral composite reading, though the buy-side insider transactions represent a constructive signal for shareholders monitoring corporate officer behavior.
AbbVie Inc. reported mixed recent quarterly results, per company earnings reports. In the most recently completed quarter ending April 2026, the company posted earnings per share of $2.65 against a consensus estimate of $2.66, representing a marginal miss of $0.01. The prior reported quarter showed EPS of $3.65 versus an analyst estimate of $3.77, resulting in a more pronounced shortfall of $0.12 per share. Both quarters reflect slight underperformance relative to Wall Street expectations. Looking ahead, analysts project EPS of $3.01 for the upcoming quarter with results expected on April 24, 2026, while the subsequent quarter's estimate stands at $3.78 with a reporting date of October 30, 2026, according to analyst estimates. The sequential increase in forward estimates from $3.01 to $3.78 suggests analysts anticipate meaningful earnings acceleration driven by AbbVie's immunology and oncology portfolio expansion beyond the Humira biosimilar competitive environment.
Wall Street consensus on AbbVie Inc. remains predominantly constructive, with recent analyst actions reaffirming positive stances according to Wall Street analyst reports. On October 13, 2026, RBC Capital reiterated its Outperform rating, while on October 8, both JP Morgan and Cantor Fitzgerald maintained Overweight designations per SID consensus data. Guggenheim reiterated its Buy rating on October 9, 2026. The sole neutral voice among recent coverage came from UBS, which maintained its Neutral rating on October 9. Notably, none of the five most recent analyst actions involved downgrades, and all represented reiterations of existing positions rather than initiations or rating changes, reflecting stable conviction levels. Four of the five analysts maintain bullish-equivalent ratings, representing an 80% positive skew in recent coverage activity. The consistency of maintained ratings suggests analysts view AbbVie's current business trajectory and pipeline developments as tracking in line with previously established investment theses across both immunology and aesthetics segments.
The latest Smart Investors Daily articles mentioning ABBV.
